Literature DB >> 19962137

Spinal muscular atrophy (SMA) after conception using gametes from anonymous donors: recommendations for the future.

Pamela Callum1, Maria Teresa Urbina, Rena E Falk, Jorge A Alvarez-Diaz, Isaac Benjamin, Charles A Sims.   

Abstract

OBJECTIVE: To discuss the diagnosis of spinal muscular atrophy in a child conceived using donor gametes.
DESIGN: None.
SETTING: None. PATIENT(S): Offspring of gamete donors. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): None. RESULT(S): A child conceived using gametes from anonymous sperm and ova donors was diagnosed with spinal muscular atrophy type 1. CONCLUSION(S): Gamete donor facilities are not required to perform extensive genetic testing on their donors; however, the well-being of the children conceived through assisted reproductive technologies should be a primary objective of reproductive medicine. The risk for specific medical problems in donor offspring can be significantly reduced by incorporating carrier screening for common, severe disorders such as spinal muscular atrophy into donor screening practices. Future efforts should focus on communicating the limitations of genetic screening to donor gamete recipients and educating them about their reproductive options. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962137     DOI: 10.1016/j.fertnstert.2009.10.039

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Expanded carrier screening in gamete donors of Venezuela.

Authors:  Maria Teresa Urbina; Isaac Benjamin; Randolfo Medina; José Jiménez; Laura Trías; Jorge Lerner
Journal:  JBRA Assist Reprod       Date:  2017-12-01

2.  Attitudes of sperm, egg and embryo donors and recipients towards genetic information and screening of donors.

Authors:  David J Amor; Annabelle Kerr; Nandini Somanathan; Alison McEwen; Marianne Tome; Jan Hodgson; Sharon Lewis
Journal:  Reprod Health       Date:  2018-02-09       Impact factor: 3.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.